Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tiziana Life Sciences PLC

1.47
-0.0124-0.84%
Volume:98.29K
Turnover:143.13K
Market Cap:163.58M
PE:-13.20
High:1.47
Open:1.46
Low:1.43
Close:1.48
Loading ...

Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis

MT Newswires Live
·
13 Jun

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab With Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

THOMSON REUTERS
·
13 Jun

Tiziana Life Sciences Announces Phase 2 Trial of Intranasal Foralumab for Alzheimer's Disease at Bio International Convention

Reuters
·
13 Jun

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

THOMSON REUTERS
·
23 May

Tiziana Life Sciences Announces Promising Results of Nasal Foralumab in Treating Moderate Alzheimer's Disease, Published in Journal of Clinical Nuclear Medicine

Reuters
·
15 May

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in Pet Scan of Moderate Alzheimer's Patient Treated With Intranasal Foralumab

THOMSON REUTERS
·
09 May

Tiziana Life Sciences Ltd. Files Amendment to 10-K Annual Report

Reuters
·
09 May

Tiziana Life Sciences Announces Comprehensive Positive Results From Study of Nasal Foralumab in Patients With Multiple Sclerosis

THOMSON REUTERS
·
06 May

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

Insider Monkey
·
30 Apr

BRIEF-Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Reuters
·
23 Apr

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

THOMSON REUTERS
·
23 Apr

BRIEF-Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial

Reuters
·
02 Apr

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

THOMSON REUTERS
·
02 Apr

Tiziana Life Sciences files $250M mixed securities shelf

TIPRANKS
·
26 Mar

Tiziana Life Sciences announces dosing of new patients at Yale MS Center

TIPRANKS
·
26 Mar

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

THOMSON REUTERS
·
25 Mar

Stocks to Watch Tuesday: Trump Media, Tesla, Samsung, GameStop -- WSJ

Dow Jones
·
25 Mar

BRIEF-Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 Million - SEC Filing

Reuters
·
25 Mar

Tiziana Life Sciences Ltd Files for Mixed Shelf of up to $250 Mln - SEC Filing

THOMSON REUTERS
·
25 Mar

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

GlobeNewswire
·
17 Mar